[go: up one dir, main page]

FI870457A0 - PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE. - Google Patents

PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE.

Info

Publication number
FI870457A0
FI870457A0 FI870457A FI870457A FI870457A0 FI 870457 A0 FI870457 A0 FI 870457A0 FI 870457 A FI870457 A FI 870457A FI 870457 A FI870457 A FI 870457A FI 870457 A0 FI870457 A0 FI 870457A0
Authority
FI
Finland
Prior art keywords
active ingredient
stabilization
interference
pharmaceutical form
ifn alpha
Prior art date
Application number
FI870457A
Other languages
Finnish (fi)
Other versions
FI870457L (en
FI86144B (en
FI86144C (en
Inventor
Helmut Franz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of FI870457A0 publication Critical patent/FI870457A0/en
Publication of FI870457L publication Critical patent/FI870457L/en
Publication of FI86144B publication Critical patent/FI86144B/en
Application granted granted Critical
Publication of FI86144C publication Critical patent/FI86144C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The pharmaceutical forms are intended for topical administration and employ as vehicle for and stabiliser of the active ingredient a composition which specifically confers special stability on the active ingredient IFN alpha. The forms are essentially composed of hydroxyethylcellulose and gelatin and preferably contain highly purified IFN alpha which has been prepared by DNA recombination as active ingredient.
FI870457A 1986-02-05 1987-02-03 FOERFARANDE FOER FRAMSTAELLNING AV PHARMACEUTICAL PREPARATFORMER FOER TOPISK ANVAENDNING FOER STABILIZERING AV -INTERFERON. FI86144C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863603444 DE3603444A1 (en) 1986-02-05 1986-02-05 PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA
DE3603444 1986-02-05

Publications (4)

Publication Number Publication Date
FI870457A0 true FI870457A0 (en) 1987-02-03
FI870457L FI870457L (en) 1987-08-06
FI86144B FI86144B (en) 1992-04-15
FI86144C FI86144C (en) 1992-07-27

Family

ID=6293372

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870457A FI86144C (en) 1986-02-05 1987-02-03 FOERFARANDE FOER FRAMSTAELLNING AV PHARMACEUTICAL PREPARATFORMER FOER TOPISK ANVAENDNING FOER STABILIZERING AV -INTERFERON.

Country Status (20)

Country Link
EP (1) EP0231816B1 (en)
JP (1) JPS62209024A (en)
KR (1) KR870007698A (en)
AT (1) ATE63823T1 (en)
AU (1) AU601712B2 (en)
CA (1) CA1295242C (en)
DD (1) DD284602A5 (en)
DE (2) DE3603444A1 (en)
DK (1) DK164202C (en)
ES (1) ES2028796T3 (en)
FI (1) FI86144C (en)
GR (1) GR3002270T3 (en)
HU (1) HU196560B (en)
IE (1) IE59697B1 (en)
IL (1) IL81472A0 (en)
NO (1) NO169638C (en)
NZ (1) NZ219169A (en)
PH (1) PH24377A (en)
PT (1) PT84243B (en)
ZA (1) ZA87793B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275804A (en) * 1986-02-25 1994-01-04 E. B. Michaels Research Associates, Inc. Process and composition for oral hygiene
DE3731255A1 (en) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilization of therapeutically active proteins in pharmaceutical preparations
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3803312A1 (en) * 1988-02-04 1989-08-10 Gerd Prof Dr Med Gross Use of an interferon-containing gel
NO179479C (en) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Process for the preparation of an intravaginal pharmaceutical preparation
ATE110571T1 (en) * 1988-05-06 1994-09-15 Toray Industries STABLE INTERFERON BETA COMPOSITION.
US5244652A (en) * 1991-03-22 1993-09-14 E. B. Michaels Research Associates, Inc. Viscous surface active composition
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
EP0607275A4 (en) * 1991-10-11 1995-02-22 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha.
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
FI106465B (en) * 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Process for the preparation of virus-safe pharmaceutical compositions
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4536194B2 (en) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 Stable injectable formulation
WO2001066084A2 (en) * 2000-03-07 2001-09-13 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
RU2004116692A (en) * 2001-11-02 2005-03-20 Секисуй Кемикал Ко., Лтд. (Jp) CYTOKINE INDUCING SUBSTANCE AND DEVICE FOR CYTOKINE INDUCTION
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
JP5740653B2 (en) * 2009-05-29 2015-06-24 イノニクス テクノロジーズ インコーポレーティッドＩｎｎｏｎｉｘ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ Composition for use in reducing human pathogen infection
RU2431489C1 (en) * 2010-05-25 2011-10-20 Федеральное государственное учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНЦРР Росмедтехнологий") Method of treating chronic inflammatory bowel diseases
EP2819682B1 (en) 2012-03-01 2017-05-03 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
JP6081156B2 (en) * 2012-11-15 2017-02-15 アルケア株式会社 Hydrogel
DE102012222365A1 (en) 2012-12-05 2014-06-05 Aesculap Ag Composition for use in the prophylaxis of post-surgical adhesions
JP2016520646A (en) * 2013-06-09 2016-07-14 エフラナット リミテッド Composition comprising Gc-macrophage activator and use thereof
KR102679493B1 (en) 2017-01-31 2024-07-01 킴벌리-클라크 월드와이드, 인크. Antibacterial composition containing benzoic acid ester and method for inhibiting bacterial growth using the same
KR20230117342A (en) 2020-10-22 2023-08-08 시퀄 바이오 인코포레이티드 Peptide preparations and ophthalmic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A (en) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト Pharmaceutical composition
JPS6069037A (en) * 1983-09-26 1985-04-19 Sunstar Inc External preparation for erythematosus
EP0139286B1 (en) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Prolonged sustained-release preparations
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS60260523A (en) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd Lyophilized drug composition of interferon

Also Published As

Publication number Publication date
FI870457L (en) 1987-08-06
IE59697B1 (en) 1994-03-23
ES2028796T3 (en) 1992-07-16
CA1295242C (en) 1992-02-04
DK164202C (en) 1992-10-19
NO169638B (en) 1992-04-13
DE3603444A1 (en) 1987-08-06
DK58387A (en) 1987-08-06
FI86144B (en) 1992-04-15
PH24377A (en) 1990-06-13
NO870441D0 (en) 1987-02-04
PT84243B (en) 1989-09-14
EP0231816A2 (en) 1987-08-12
GR3002270T3 (en) 1992-12-30
DK164202B (en) 1992-05-25
ZA87793B (en) 1988-10-26
ATE63823T1 (en) 1991-06-15
HUT43494A (en) 1987-11-30
DD284602A5 (en) 1990-11-21
IE870295L (en) 1987-08-05
NZ219169A (en) 1990-04-26
NO870441L (en) 1987-08-06
DE3770280D1 (en) 1991-07-04
AU6829287A (en) 1987-08-06
PT84243A (en) 1987-03-01
FI86144C (en) 1992-07-27
HU196560B (en) 1988-12-28
IL81472A0 (en) 1987-09-16
KR870007698A (en) 1987-09-21
DK58387D0 (en) 1987-02-04
JPS62209024A (en) 1987-09-14
AU601712B2 (en) 1990-09-20
NO169638C (en) 1992-07-22
EP0231816A3 (en) 1987-09-23
EP0231816B1 (en) 1991-05-29

Similar Documents

Publication Publication Date Title
FI870457A0 (en) PHARMACEUTICAL FORM FOR STABILIZATION OF THE INTERFERENCE.
DE3581819D1 (en) PYRIDAZINE AMINS EFFECTIVE AGAINST VIRUSES.
FI871750A0 (en) NASAL ADMINISTRATION AV CEILINGS MODEL.
ATE188119T1 (en) REMEDIES FOR WOUNDS AND HEMORRHOIDS
IE781032L (en) Pharmaceutical compositions
FI843560A7 (en) Mevalonolactone analogues and derivatives thereof, methods for their preparation, pharmaceutical compositions containing them and their use as pharmaceutical agents.
NO165071C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 7- (3-AMINO-1-PYRROLIDINYL) -8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4, -DIHYDRO-4-OXO-3-CHINOLINE-CARBOXYL.
KR890005088A (en) 4-aminopyridine derivatives and acid addition salts thereof
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
GB2021409A (en) Pharmaceutical composition
IT8620208A0 (en) SUBSTITUTED 7-OXABICICHLOHEPTANETHERS AS PROSTAGLANDIN ANALOGUES AND RELATED PHARMACEUTICAL COMPOSITIONS.
FR2691149B1 (en) NOVEL THIOCHROMANIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
FR2694005B1 (en) New aminoalkylchromones, methods for their preparation and pharmaceutical compositions containing them.
EP0355899A3 (en) Nucleotide derivatives
DK0578535T3 (en) New peptide derivatives active in cell adhesion processes, processes for their preparation, and pharmaceutical compositions containing the derivatives
FI894813A0 (en) Process for the preparation of therapeutically active 2-methoxycarbonyl-substituted N, N'-di (trimethoxybenzoyl) piperazine derivatives
IT8125874A0 (en) THERAPEUTIC COMPOSITIONS WITH CHOLERETIC ADAPTIVITY CONTAINING DERIVED FROM CHOLANIC ACID AS THE ACTIVE INGREDIENT.
NO863005D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,4,5,6,7,8-HEXSAHYDRO-2-ALKYL-4-ARYL-5-OXO-1,7-NAFTYRIDINE-3-CARBOXYL ACID ESTER DERIVATIVES.
FR2691967B1 (en) NOVEL PYRROLOTHIENOPYRAZINIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR860002498A (en) Pharmaceutical Compositions of 1,4-Dihydropyridine Derivatives
FR2567755B1 (en) NEW ANTI-TUMOR DRUG CONTAINING TRIACETOXY-1,8,9 ANTHRACENE AS ACTIVE INGREDIENT
IT8819541A0 (en) PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION.

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: DR. KARL THOMAE GESELLSCHAFT MIT